Sweeney et al. showed in 2017 that tesevatinib (TSV), a multi-kinase inhibitor (especially effective for the EGFR family), reduced phosphorylation of key mediators of cystogenesis and alleviated renal and biliary disease in bpk and PCK models of ARPKD (Sweeney et al., 2017). Here, EGFR is linked to autosomal recessive polycystic kidney disease.